Benzonatate Should Not Be Used Long-Term for Persistent Dry Cough
Benzonatate is FDA-approved only for symptomatic relief of cough and is not intended for long-term use—you should instead follow guideline-based algorithms to identify and treat the underlying cause of persistent dry cough rather than continuing benzonatate beyond short-term symptomatic management 1, 2.
Why Long-Term Benzonatate Use Is Problematic
Lack of Evidence for Chronic Use
The FDA label indicates benzonatate is for "symptomatic relief of cough" with dosing "as needed," not for continuous long-term therapy 1. A systematic review found that benzonatate's approval is based on evidence that "would not stand up to current regulatory review," with substantial limitations in existing evidence regarding clinical effectiveness and safety 3. The available studies used very small populations and limited clinical settings, raising concerns about generalizability 3.
Significant Safety Concerns
Acute toxicity risks:
- Hypersensitivity reactions including bronchospasm, laryngospasm, and cardiovascular collapse (particularly if capsules are chewed or sucked) 1
- CNS effects: sedation, dizziness, mental confusion, visual hallucinations 1
- Deliberate or accidental overdose has resulted in death, particularly in children 1
- Rapid onset of severe toxicity (often <5 minutes) with cardiac arrest, seizures, and dysrhythmias in overdose 4
Local tissue toxicity: Recent research demonstrates that benzonatate causes significant myotoxicity and inflammation even at subtherapeutic concentrations when used as a local anesthetic 5. While this was studied in peripheral nerve injection, it raises concerns about chronic exposure effects.
No carcinogenicity data in humans: While rodent studies showed no carcinogenic potential 6, there are no long-term human safety studies for chronic use.
What You Should Do Instead
Follow the Guideline-Based Approach for Chronic Cough
For a patient with persistent dry cough and normal chest X-ray, the CHEST guidelines provide a clear algorithm 2:
1. Screen for red flags (hemoptysis, smoker >45 with new cough, systemic symptoms, weight loss, recurrent pneumonia) 2
2. Check medication history:
- Discontinue ACE inhibitors or sitagliptin for at least 4 weeks if present 2
3. Assess for the three most common causes:
- Upper airway cough syndrome (postnasal drip)
- Asthma/eosinophilic bronchitis (may require bronchial hyperresponsiveness testing or therapeutic corticosteroid trial)
- GERD (treatment should include more than just acid suppression) 2
4. Optimize therapy for each identified diagnosis:
- Maintain all partially effective treatments due to possibility of multiple causes 2
- Follow up in 4-6 weeks to assess compliance and response 2
5. For unexplained chronic cough after thorough workup:
- Consider multimodality speech pathology therapy 7
- Consider gabapentin trial (300 mg once daily, escalating to maximum 1,800 mg/day in divided doses) after discussing risk-benefit profile 7
- Reassess at 6 months before continuing 7
Common Pitfalls to Avoid
- Don't continue symptomatic treatment without investigating the cause—this delays diagnosis and appropriate management 2
- Don't limit GERD treatment to acid suppression alone—this is explicitly emphasized in guidelines 2
- Don't prescribe inhaled corticosteroids if testing for bronchial hyperresponsiveness and eosinophilia is negative 7
- Don't use PPIs if workup for acid reflux is negative 7
Bottom Line
Discontinue the benzonatate and work through the chronic cough algorithm systematically. The goal is to identify and treat the underlying cause(s), not to suppress the symptom indefinitely with an agent that lacks evidence for long-term safety or efficacy and carries significant toxicity risks 2, 7, 3.